Alterity Therapeutics
ATHE
21 hedge funds and large institutions have $454K invested in Alterity Therapeutics in 2015 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 6 closing their positions.
4% less call options, than puts
Call options by funds: $43K | Put options by funds: $45K
13% less funds holding
Funds holding: 24 → 21 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
65% less capital invested
Capital invested by funds: $1.29M → $454K (-$834K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KA
Kovack Advisors
Ft. Lauderdale,
Florida
|
+$20.5K |
| 2 |
Group One Trading
Chicago,
Illinois
|
+$18.6K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$14.8K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$6.38K |
| 5 |
TWA
TCI Wealth Advisors
Tucson,
Arizona
|
+$798 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$189K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$178K |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$136K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$61.7K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$35K |
ATHE Hedge Fund Activity: Q1 2015 in Review
21 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2015, worth a combined $454K — down 65% from $1.29M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of ATHE and 3 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 3 added.
The largest buyer was Kovack Advisors, opening a new position worth an estimated $20.5K. The largest seller was Virtu KCG Holdings, cutting an estimated $189K.
- 21 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2015, down from 24 in Q4 2014.
- Funds reported $454K of Alterity Therapeutics stock for Q1 2015, down 65% quarter-over-quarter.
- 3 funds opened new Alterity Therapeutics positions in Q1 2015 and 6 closed out, a net change of -3 holders.
- The largest Alterity Therapeutics buyer in Q1 2015 was Kovack Advisors, an estimated $20.5K added.
- The largest Alterity Therapeutics seller in Q1 2015 was Virtu KCG Holdings, an estimated $189K sold.
Based on aggregated 13F filings for Q1 2015.